Docetaxel With or Without Metronomic Cyclophosphamide as First Line Chemotherapy in Metastatic Breast Cancer
The purpose of this study is to evaluate the role of metronomic cyclophosphamide in addition to docetaxel in first line therapy in metastatic breast cancer.
Breast Cancer
DRUG: Docetaxel and Cyclophosphamide (TC)|DRUG: Docetaxel (T)
Progression Free Survival, 6 weeks
Biomarker serum VEGF level, Relationship of serum VEGF level and efficacy, 6 weeks|Biomarker immuno-marker, Relationship of immuno-marker(CD3,CD4,CD8 ect) and efficacy, 6 weeks|Efficacy Overall Response Rate, Overall Response Rate, 6 weeks|Efficacy Overall Survival, Overall Survival, OS, 6 weeks|Safety, Safety（NCI CTCAE v4.0）, 6 weeks|genetic polymorphisms, To evaluate the relationship of genetic polymorphisms and efficacy., 6 weeks
Metronomic chemotherapy has been considered as an effective strategy for metastatic breast cancer. This trial is designed to evaluate the role of metronomic cyclophosphamide in addition to docetaxel in first line therapy in metastatic breast cancer.